Current Report · Items 8.01, 9.01 · 8-K

Bicara Therapeutics Inc.

BCAXNASDAQEQUITYCurrent

Other Events

Item 8.01 - Other Events. On February 19, 2026, Bicara Therapeutics Inc. issued a press release entitled “Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Filed Feb 19, 2026Accepted Feb 19, 2026, 4:32 PM ESTCIK 2023658Accession 0001628280-26-009808

View company →Permanent SEC source ↗

Press release in this filing

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen →

Company context

Current securities

BCAXNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

Bicara Therapeutics Inc. · 8-K · Filed 2026-02-19

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value

Symbol: BCAX
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: c-1

Dimensions: Not supplied

Accession 000162828026009808 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Get the free weekly BCS email.